^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NGC-capecitabine (PCS6422)
i
Other names: PCS6422, ADH300004, NGC-Cap
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Elion Oncology, Processa Pharma
Drug class:
DPYD inhibitor
Related drugs:
over1year
PCS6422-GI-01: A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors (clinicaltrials.gov)
P1, N=23, Completed, Processa Pharmaceuticals | Active, not recruiting --> Completed
Trial completion • Metastases
|
capecitabine • NGC-capecitabine (PCS6422)
over1year
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=90, Recruiting, Processa Pharmaceuticals
New P2 trial • Metastases
|
capecitabine • NGC-capecitabine (PCS6422)
over1year
A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors (clinicaltrials.gov)
P1, N=23, Active, not recruiting, Processa Pharmaceuticals | Recruiting --> Active, not recruiting | Phase classification: P1b --> P1 | N=42 --> 23 | Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
capecitabine • NGC-capecitabine (PCS6422)
over2years
A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors (clinicaltrials.gov)
P1b, N=42, Recruiting, Processa Pharmaceuticals | Trial primary completion date: Sep 2023 --> Jan 2024
Trial primary completion date • Metastases
|
capecitabine • NGC-capecitabine (PCS6422)
Share via
